Population pharmacokinetics of cyclosporine A in pediatric patients with thalassemia undergoing allogeneic hematopoietic stem cell transplantation
ConclusionIn the PPK model based on the pediatric cohort on CsA with thalassemia undergoing allogeneic HSCT, WT, POD, FLUC, VORI, POSA, and RBC were found to be the significant factors influencing CL of CsA. The reliability and robustness of the final model were excellent. It is expected that the PPK model can assist in individualizing dosing strategy clinically. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - April 11, 2024 Category: Drugs & Pharmacology Source Type: research
CD44 expression in renal tubular epithelial cells in the kidneys of rats with cyclosporine-induced chronic kidney disease
In this study, we investigated CD44 expression and its role in renal fibrogenesis in a cyclosporine (CyA) rat model of CKD. Seven-week-old male Sprague-Dawley rats fed a low-salt diet were subcutaneously administered CyA (0, 15, or 30 mg/kg) for 28 days. CD44 was expressed in atrophic, dilated, and hypertrophic TECs in the fibrotic lesions of the CyA groups. These TECs were collected by laser microdissection and evaluated by microarray analysis. Gene ontology analysis suggested that these TECs have a mesenchymal phenotype, and pathway analysis identified CD44 as an upstream regulator of fibrosis-related genes, including fi...
Source: Journal of Toxicologic Pathology - April 8, 2024 Category: Toxicology Authors: Kohei Matsushita Takeshi Toyoda Hirotoshi Akane Tomomi Morikawa Kumiko Ogawa Source Type: research
Risk of Developing Hypertension in Atopic Dermatitis Patients Receiving Long-term and Low-dose Cyclosporine: A Nationwide Population-based Cohort Study
CONCLUSION: The incidence of CS-associated hypertension is very low when using low-dose treatment regimens for AD. However, the current use or a high cumulative dose of CS for treating patients with AD increases the risk of developing hypertension. Precaution is needed when prescribing CS for long-term treatment of AD.PMID:38576249 | DOI:10.5021/ad.23.099 (Source: Annals of Dermatology)
Source: Annals of Dermatology - April 5, 2024 Category: Dermatology Authors: Yu Ri Woo Arum Choi Seo Won Song Suyeun Kim Sang Wook Son Sang Hyun Cho Sukil Kim Jung Eun Kim Source Type: research
Risk of Developing Hypertension in Atopic Dermatitis Patients Receiving Long-term and Low-dose Cyclosporine: A Nationwide Population-based Cohort Study
CONCLUSION: The incidence of CS-associated hypertension is very low when using low-dose treatment regimens for AD. However, the current use or a high cumulative dose of CS for treating patients with AD increases the risk of developing hypertension. Precaution is needed when prescribing CS for long-term treatment of AD.PMID:38576249 | PMC:PMC10995617 | DOI:10.5021/ad.23.099 (Source: Annals of Dermatology)
Source: Annals of Dermatology - April 5, 2024 Category: Dermatology Authors: Yu Ri Woo Arum Choi Seo Won Song Suyeun Kim Sang Wook Son Sang Hyun Cho Sukil Kim Jung Eun Kim Source Type: research
